• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Antiangiogenic therapy and immune checkpoint blockade go hand in hand.抗血管生成疗法与免疫检查点阻断相辅相成。
Ann Transl Med. 2017 Dec;5(24):497. doi: 10.21037/atm.2017.10.12.
2
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.治疗性癌症疫苗与抗血管生成疗法和免疫检查点阻断联合应用。
Front Immunol. 2019 Mar 14;10:467. doi: 10.3389/fimmu.2019.00467. eCollection 2019.
3
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.免疫检查点抑制剂与抗血管生成药物联用的不良事件：一项系统综述。
Front Pharmacol. 2019 Oct 17;10:1173. doi: 10.3389/fphar.2019.01173. eCollection 2019.
4
Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.重新审视免疫检查点阻断时代的抗血管生成多激酶抑制剂：索拉非尼的案例。
Cancer Res. 2022 Oct 17;82(20):3665-3667. doi: 10.1158/0008-5472.CAN-22-2639.
5
Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis.免疫检查点抑制剂联合抗血管生成药物治疗肝细胞癌的疗效和安全性：一项系统评价和荟萃分析。
Front Oncol. 2022 Aug 18;12:964779. doi: 10.3389/fonc.2022.964779. eCollection 2022.
6
Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
7
Immunotherapy for sarcomas.肉瘤的免疫治疗。
Jpn J Clin Oncol. 2021 Apr 1;51(4):523-537. doi: 10.1093/jjco/hyab005.
8
Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.病例报告：抗血管生成治疗联合免疫检查点抑制剂与肿瘤内冷冻消融治疗肝细胞癌。
Front Immunol. 2021 Oct 18;12:740790. doi: 10.3389/fimmu.2021.740790. eCollection 2021.
9
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
10
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.乳腺癌的联合放射治疗与免疫检查点阻断治疗
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029. Epub 2017 May 26.

引用本文的文献

1
Silver Jubilee of HER2 targeting: a clinical success in breast cancer.HER2靶向治疗二十五周年：乳腺癌治疗领域的临床成功典范
J Natl Cancer Cent. 2025 Feb 12;5(4):379-391. doi: 10.1016/j.jncc.2024.12.008. eCollection 2025 Aug.
2
Lipid Nanoparticle Delivery System for Normalization of Tumor Microenvironment and Tumor Vascular Structure.用于肿瘤微环境和肿瘤血管结构正常化的脂质纳米颗粒递送系统。
Biomater Res. 2025 Feb 11;29:0144. doi: 10.34133/bmr.0144. eCollection 2025.
3
Novel tumor gene expression signatures improve the overall survival prediction efficiency over tumor mutation burden and PD-L1 expression in bladder carcinoma with checkpoint blockade immunotherapy.在采用检查点阻断免疫疗法治疗的膀胱癌中，新型肿瘤基因表达特征在总体生存预测效率方面优于肿瘤突变负荷和PD-L1表达。
Am J Cancer Res. 2024 Sep 15;14(9):4411-4428. doi: 10.62347/TIMD7591. eCollection 2024.
4
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.STING 激活纳米颗粒使血管免疫界面正常化，从而增强癌症免疫治疗。
Sci Immunol. 2023 May 12;8(83):eadd1153. doi: 10.1126/sciimmunol.add1153. Epub 2023 May 5.
5
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience.用于既往未治疗的转移性肾细胞癌的联合免疫检查点阻断方案：埃默里大学温希普癌症研究所的经验
J Immunother Precis Oncol. 2022 Jun 14;5(3):52-57. doi: 10.36401/JIPO-22-2. eCollection 2022 Aug.
6
Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.恶性胸膜间皮瘤的分子改变：通过靶向 YAP 实现有效治疗的希望。
Target Oncol. 2022 Jul;17(4):407-431. doi: 10.1007/s11523-022-00900-2. Epub 2022 Jul 30.
7
Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.重新审视抗血管生成治疗：重塑晚期非小细胞肺癌的治疗格局。
Arch Pharm Res. 2022 Apr;45(4):263-279. doi: 10.1007/s12272-022-01382-6. Epub 2022 Apr 21.
8
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.胶质母细胞瘤中抗血管生成疗法与免疫疗法之间的相互作用
Front Oncol. 2022 Jan 12;11:812916. doi: 10.3389/fonc.2021.812916. eCollection 2021.
9
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.抗血管生成抗体 BD0801 联合免疫检查点抑制剂具有协同抗肿瘤活性，并影响肿瘤微环境。
BMC Cancer. 2021 Oct 22;21(1):1134. doi: 10.1186/s12885-021-08859-5.
10
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images.预测非小细胞肺癌对免疫检查点抑制剂（ICI）免疫治疗反应的生物标志物：从细胞到体内成像
Cancers (Basel). 2021 Sep 10;13(18):4543. doi: 10.3390/cancers13184543.

本文引用的文献

1
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.联合抗血管生成和抗PD-L1疗法通过形成高内皮微静脉刺激肿瘤免疫。
Sci Transl Med. 2017 Apr 12;9(385). doi: 10.1126/scitranslmed.aak9679.
2
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.双重血管生成素-2 和 VEGFA 抑制引发抗肿瘤免疫，这种免疫可被 PD-1 检查点阻断增强。
Sci Transl Med. 2017 Apr 12;9(385). doi: 10.1126/scitranslmed.aak9670.
3
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.通过靶向骨髓细胞中的PI3Kγ克服对检查点阻断疗法的耐药性。
Nature. 2016 Nov 17;539(7629):443-447. doi: 10.1038/nature20554. Epub 2016 Nov 9.
4
PI3Kγ is a molecular switch that controls immune suppression.磷脂酰肌醇-3激酶γ（PI3Kγ）是一种控制免疫抑制的分子开关。
Nature. 2016 Nov 17;539(7629):437-442. doi: 10.1038/nature19834. Epub 2016 Sep 19.
5
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.癌症治疗的未来：免疫调节、嵌合抗原受体及联合免疫疗法。
Nat Rev Clin Oncol. 2016 Jun;13(6):394. doi: 10.1038/nrclinonc.2016.65. Epub 2016 Apr 26.
6
Antiangiogenic therapy in oncology: current status and future directions.肿瘤学中的抗血管生成治疗：现状与未来方向。
Lancet. 2016 Jul 30;388(10043):518-29. doi: 10.1016/S0140-6736(15)01088-0. Epub 2016 Feb 5.
7
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.肿瘤内髓样细胞调节对抗血管生成治疗的反应性和抗性。
Cell Rep. 2015 Apr 28;11(4):577-91. doi: 10.1016/j.celrep.2015.03.055. Epub 2015 Apr 16.
8
Targeting the tumor vasculature to enhance T cell activity.靶向肿瘤血管以增强T细胞活性。
Curr Opin Immunol. 2015 Apr;33:55-63. doi: 10.1016/j.coi.2015.01.011. Epub 2015 Feb 6.
9
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.抗血管生成策略再探讨：从饿死肿瘤到缓解缺氧
Cancer Cell. 2014 Nov 10;26(5):605-22. doi: 10.1016/j.ccell.2014.10.006.
10
Innate and adaptive immune cells in the tumor microenvironment.肿瘤微环境中的固有和适应性免疫细胞。
Nat Immunol. 2013 Oct;14(10):1014-22. doi: 10.1038/ni.2703.

Antiangiogenic therapy and immune checkpoint blockade go hand in hand.

作者信息

Campesato Luis Felipe, Merghoub Taha

机构信息

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, NY, USA.

出版信息

Ann Transl Med. 2017 Dec;5(24):497. doi: 10.21037/atm.2017.10.12.

DOI:10.21037/atm.2017.10.12
PMID:29299458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5750272/
Abstract
摘要